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Abstract
Background Angiogenesis plays a pivotal role in neo-
plastic growth and metastasis formation. Vascular endo-
thelial growth factor A (VEGFA) is a major player in
physiological and tumour-induced angiogenesis and
numerous human tumours have been show to overexpress
VEGFA. Moreover increased VEGFA gene expression has
been found frequently to correlate with tumour progres-
sion, recurrences and survival. Interestingly, several studies
have demonstrated that gene amplification may result in
protein overexpression and that amplification of the ther-
apeutics’ target gene can serve as an excellent predictive
marker (i.e. HER2 and trastuzumab). However the impact
of VEGFA gene amplification has been only recently
assessed for some cancer types such as osteosarcoma,
colorectal, breast and liver cancer.
Aims This study aimed to assess VEGFA gene amplifi-
cation status using fluorescent in situ hybridization (FISH)
in a large cohort of different tumour entities. Thus, we
investigated the incidence of VEGFA amplification using a
multi-tumour tissue microarray (TMA) containing 2,837
evaluable specimens from 80 different tumour entities and
31 normal tissue types. Moreover, we validated FISH
analysis as reference method to evaluate VEGFA gene
status by comparing it to comparative genomic hybridiza-
tion (CGH).
Results We observed that VEGFA locus amplification
and/or polysomy represented a small but regularly detected
population in several tumour entities while was not present
in normal tissues. VEGFA gene alterations were predomi-
nantly observed in hepatocarcinomas, adenocarcinomas of
the pancreas and intestine, large cell carcinoma of the lung
and in endometrium serous carcinoma. Furthermore our
data demonstrated that VEGFA detection by FISH provided
highly comparable results to those generated by CGH.
Conclusion Albeit with low percentage, VEGFA ampli-
fication is commonly observed across several tumour
entities. Furthermore, our results demonstrated that FISH
test could be used as a reliable diagnostic tool to evaluate
VEGFA gene status in human specimens.
Keywords VEGFA  Gene amplification  6p12 
FISH  TMA
Introduction
Vascular endothelial growth factor A (VEGFA) is a growth
factor acting as a key regulator of proliferation, survival,
migration and permeability of blood endothelial cells (ECs)
in both physiological and pathological angiogenesis [1]. In
the human genome, the VEGFA gene is located on the short
arm of chromosome 6 (Chr6), at position p12–21. Among
the different VEGFA isoforms (up to 12 have been
described), VEGFA 165 is the most prevalent one and it is
overexpressed in several human solid tumours [1].
Vascular endothelial growth factor A tumour-mediated
angiogenesis is a critical step in both tumour growth and
metastasis formation [1]. The majority of studies using either
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immunohistochemistry (IHC) or other approaches for the
detection of VEGFA protein and mRNA in tumour tissues as
well as the detection of VEGFA plasma levels, all point
towards a significant negative prognostic survival effect of
increased VEGFA expression in cancer patients [2]. Subse-
quently, in the last decade several anti-angiogenic agents have
been developed and some, such as Bevacizumab (BV)
(Roche, Basel, Switzerland), a recombinant humanized
monoclonal antibody that prevents VEGFA binding to both its
receptors (VEGFR1 and VEGFR2), are in clinical use [3, 4].
Nevertheless, the clinical benefits of anti-angiogenic therapy
are limited and recent data report that a number of tumours,
although initially responding to VEGFA inhibition, become
resistant at later stages of treatment [1]. Furthermore, it has
been demonstrated that in some experimental models, anti-
angiogenic therapy may even increase tumour aggressiveness
and metastatic burden [5]. Therefore, there is an urgent need
for the identification and validation of biomarkers that predict
response towards anti-angiogenic treatments and allow the
monitoring of therapeutic benefit and toxicity.
Recently, we analysed two independent colorectal cancer
(CRC) cohorts using a non-commercial, house made fluo-
rescent in situ hybridization (FISH) probe covering the
VEGFA chromosomal region and reported that VEGFA gene
locus (6p12) amplification identified a small but highly
aggressive subset of CRCs [6]. In both cohorts, VEGFA gene
amplification was significantly linked to more unfavourable
prognostic features including advanced stage, vascular and
lymphatic invasion and significantly poorer survival time
[6]. Furthermore, it has been recently demonstrated that
VEGFA amplification in univariate analysis was associated
with poor outcomes in breast cancer, mainly in Her2? as
well as triple negative breast cancers [7]. However despite
the fact that the evaluation of VEGFA gene status has been
shown to be an important parameter to predict disease pro-
gression, a comprehensive study investigating its status in
different tumours is still missing.
In this work, we investigated the incidence of VEGFA gene
locus amplification across a large tissue collective made of 80
different cancer entities taking advantage of a multi-tumour
tissue microarray (TMA) with 2,837 evaluable specimens. In
addition, we compared our FISH data with comparative
genomic hybridization (CGH) analysis data, in order to
investigate the effectiveness and reliability of our FISH test as
a diagnostic tool to assess the VEGFA gene status.
Materials and methods
Tissue microarrays
A pre-existing set of six TMAs with 3,417 tissue samples
from 80 tumour entities and 31 normal tissue types was
used in this study [8, 9]. All tissue samples were retrieved
from the archives of the Institute of Pathology (University
of Basel, Switzerland) and were reviewed by experienced
pathologists (L.T. and L.M.T.). Briefly, to construct the
TMAs, tissue samples were fixed in buffered 4 % formalin
and embedded in paraffin. H&E-stained sections were
made from each selected primary block (named donor
blocks) to define representative tissue regions. Tissue cyl-
inders (0.6 mm in diameter) were then punched from the
region of the donor block with the use of a custom-made
precision instrument (Beecher Instruments, Silver Spring,
USA). Afterwards, tissue cylinders were transferred to a
25 9 35 mm paraffin block to produce the TMAs. The
resulting TMA block was cut into 3-lm sections that were
transferred to glass slides by use of the paraffin sectioning
aid system (Instrumedics, Hackensack, USA). Sections
from the TMA blocks were used for FISH analysis. The use
of the clinical samples from the biobank of the Institute of
Pathology for the TMA construction was approved by the
Ethics Committee of the University Hospital of Basel
(EKBB). In addition, we used a second set of three TMAs
comprising a total of 194 tissue samples obtained from 24
different human tumour-derived xenograft types in nude
mice models (Oncotest GmbH, Freiburg, Germany).
Preparation of FISH probe
The genomic BAC clone RPCIB753M0921Q (imaGENES
GmbH, Berlin, Germany), which covers the VEGFA
genomic region (6p12) was used for preparation of the
FISH probe. A starter culture of 2–5 ml LB medium was
inoculated with the BAC clone and 0.5 ml of the starter
culture was diluted in 500 ml selective LB medium. BAC-
DNA was isolated using the Large-Construct Kit (Qiagen,
Hombrechtikon, Switzerland) according to the manufac-
turer’s instructions. BAC identity was verified by
sequencing using 1 lg of isolated DNA and 20 pmol of
SP6, using T7 primers (EuroFins MGW Operon, Ebers-
berg, Germany). 1 lg of isolated BAC-DNA was digested
with Alu I restriction enzyme (Invitrogen, Lucerne, Swit-
zerland) and labelled with Cy3-dUTP (GE Healthcare,
Buckinghamshire, UK) using the BioPrime Array CGH Kit
(Invitrogen, Lucerne, Switzerland). Labeling reaction was
assessed by usage of a Nanodrop assay (Nanodrop, Wil-
mington, USA). The labelled DNA was purified by using
the FISH Tag DNA Kit (Invitrogen, Lucerne, Switzerland).
FISH analysis
TMAs were subjected to pre-treatment as previously
described [10]. FISH probe was applied and after a dena-
turation step (10 min at 75 C), the slides were incubated
over night at 37 C. Slides were afterward washed with
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washing buffer (2X SSC, 0.3 % NP40, pH 7–7.5) and slides
were counterstained with DAPI I solution (1,000 ng/ml)
(Vysis Inc. Abbott Molecular, Abbott Park, USA). As
reference, a Spectrum Green-labelled Chr6 centromeric
probe (CEP6) (Vysis Inc. Abbott Molecolar, Abbott Park,
USA) was used. Images were obtained by usage of a Zeiss
fluorescence microscope using a 63X objective (ZEISS,
Feldbach, Switzerland) and the Axiovision software
(ZEISS, Feldbach, Switzerland). Two expert pathologists
counted a minimum of 100 tumour nuclei signals in four
separate regions of the tissue section independently; con-
sensus on non-matching results was achieved.
FISH results were interpreted according to: (1) absolute
Chr6 copy number or (2) the ratio VEGFA gene/Chr6 copy
number. We classified as not amplified samples with a
VEGFA/Chr6 ratio of \1.8; equivocal/borderline with a
VEGFA/Chr6 ratio between 1.8 and 2.2, amplified with a
VEGFA/Chr6 ratio higher than 2.2, as proposed by the
ASCO/CAP guidelines for HER2 amplification in breast
cancer [11]. Polysomy of Chr6 was defined as an average
of the Chr6 copy number. When the average was included
between 2.26 and 3.75, the polysomy 6 was defined as low
whereas, when the average was[3.75 the polysomy 6 was
defined high [12–15]. In addition, we have further cate-
gorized the amplified samples using a second selection
criterion (referred in the tables as: alternative cut off cri-
terion) discriminating between high (i.e. [10 VEGFA/
Chr6), average (5–10 VEGFA/Chr6) or low number of gene
copies.
Micro-vessel density (MVD) quantification
To evaluate micro-vessel density MVD, CD31 Ab (Ven-
tana, Cat. Num: 760-4378; pre-diluted) was used as marker
of blood vessels. Immunostaining was performed using
Benchmark XT system (Ventana) according to the man-
ufacturer’s guidelines. MVD was assessed on a small
cohort of CRCs (total n = 10, not amplified n = 3, poly-
somic n = 4, amplified n = 3). Staining evaluation and
vessel counting (number of vessel per field—0.74 mm2)
were performed by two expert pathologists in a blinded
manner (L.T. and L.M.T.).
Xenograft mouse
Human derived tumour tissue was cut into pieces of
4–5 mm edge length. For implantation 4–6 week old
homozygous nude mice were used. Briefly, once mice were
fully anesthetized, the skin and sub cutis were carefully
separated by using scissors in order to form a ‘‘subcuta-
neous pocket’’ on the animal’s flank, where one tumour
fragment per side was placed. After equipping the animal
with a unique identification tag (ear tag or transponder), the
animal was disinfected and put to fresh cage for recovery
from the anaesthesia. Afterwards, tumours growing sub-
cutaneously in nude mice were explanted and prepared by
removal of visible necrotic areas, large blood vessels and
surrounding mouse tissue (pseudo-capsule). Immediately
after, samples were snap frozen in liquid nitrogen and
stored at -80 C. Additional tissues were collected for
TMAs preparation.
DNA preparation
DNA was extracted from snap frozen tumour xenografts.
Tumours were digested with proteinase K at 55 C over-
night and the lysate treated with DNAse-free RNAse
(Qiagen, Hombrechtikon, Switzerland). DNA was extrac-
ted by phenol:chloroform:isoamylalcohol and precipitated
by ethanol. DNA pellets were then washed and resus-
pended in TElow. The integrity of each DNA preparation
was checked on a 1.3 % agarose gel and the purity ana-
lysed using NanoDrop 2000 (Thermo Scientific, Canada).
CGH array profiling
DNA was hybridized to 244 K whole-genome Agilent
arrays at Shangai Biochip Ltd, China, according standard
internal procedure. In brief, 1.5 lg of DNA were frag-
mented by a double enzymatic digestion (AluI ? RsaI)
for 2 h at 37 C followed by enzymes inactivation at
95 C. Digested DNA checked on a 0.8 % agarose gel
prior to labelling and hybridization. Digested DNA were
labelled by random priming with CY5-dCTPs and CY3-
dCTP, respectively, and hybridized at 65 C for 40 h. The
chips were scanned on an Agilent Scanner and image
analysis was done using the Feature-Extraction V10.7.3.1
software (Agilent Technologies). Feature-Extraction was
used for the fluorescence signal acquisition from the
scans. Normalization was done using the ranking-mode
method available in the Feature-Extraction V10.7.3.1
software.
Data analysis
FISH data were summarized into tables and relative per-
centage of gene amplification as well as chromosomal
polysomy were calculated for each tumour. Concerning
CGH results, array data were analysed and processed with
R [16] and the Bioconductor software framework [17],
using the snapCGH package [18] for normalization, as well
as custom routines for data processing and visualizations.
Segmentation for subsequent calling of chromosomal
aberrations was done using the circular binary segmenta-
tion algorithm [19] already implemented in the Biocon-
ductor package DNAcopy [20].
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Results
VEGFA locus amplification is observed in a large
subset of tumour types
In order to investigate the incidence of VEGFA gene locus
amplification across several tumour types, we took
advantage of a FISH VEGFA specific probe to screen a set
of multi-tumour TMAs. Out of the 3,417 tissue samples
composing our set of tissues (including 315 normal spec-
imens as controls) and representing 80 different tumour
entities, 2,837 were evaluable by FISH. Causes of exclu-
sion were either the absence of tissue punch or poor
hybridization quality.
Our analysis revealed VEGFA amplification in 10 dif-
ferent tumour types with prevalence rates between 1.5 %
and 5 % (Table 1 and Supplementary Table 1 for complete
list). Representative pictures of amplified samples as
detected using FISH are shown in Fig. 1. Since an increased
gene copy number can also be caused by polysomy instead
of focal amplification, we further investigated the polyso-
mic status of Chr6, as defined by Ma et al. [15]. We
observed polysomy of Chr6 in 18 of the 80 analysed tumour
types (Table 1 and Supplementary Table 1). In addition, we
have further categorized the amplified samples using
another selection criterion discriminating between high (i.e.
[10 VEGFA/Chr6), average (5–10 VEGFA/Chr6) or low
number of gene copies (Supplementary Table 2 and Sup-
plementary Table 3). Some tumours such as gallbladder
adenocarcinoma, squamous cell carcinoma of the larynx,
ovary (both serous and endometrioid carcinoma subtypes)
and stomach adenocarcinoma of intestinal type showed
both amplified and polysomic cases with serous endome-
trium carcinoma and large cell lung carcinoma having the
highest incidence of 16 and 10 % of cases, respectively. Of
note, in our investigation none of the breast cancer samples
from either ductal (n = 30), medullary (n = 50) or
mucinous (n = 16) subtypes were found to feature VEGFA
focal amplification, conversely polysomy was observed in
all of them, with an incidence of 3, 2 and 6 %, respectively
(Table 1).
Furthermore, across the all tumour species analysed, the
sum of cases with either focal VEGFA gene amplification
and/or polysomy of Chr6 revealed prevalence rates up to
16 % (endometrium–serous carcinoma, Table 1). As
expected neither genomic amplification of VEGFA nor
polysomy was detected in any of the normal control sam-
ples (Supplementary Table 1).
Finally, in order to investigate whether VEGFA amplifi-
cation induces increased vessel density as a result of VEGFA
overproduction, we performed MVD IHC-based evaluation
on a small cohort of CRCs (total n = 10, not amplified
n = 3, polysomic n = 4, amplified n = 3) specimens using
CD31 as marker of blood vessels. Representative pictures of
CD31 staining are presented in Fig. 1a. Our analysis
revealed that CRC samples harbouring VEGFA amplifica-
tion present with increased MVD compared to both not
amplified and polysomic specimens (Fig. 2b).
Table 1 Rates of VEGFA gene locus amplification in selected tumour types as evaluated by FISH
Organ Tumor type Amplification (%) Polysomy (%) Amplification ? polysomy (%)
Breast (n = 96) Ductal cancer (n = 30) 0 (n = 0) 3.3 (n = 1) 3.3 (n = 1)
Medullary cancer (n = 50) 0 (n = 0) 2 (n = 1) 2 (n = 1)
Mucinous cancer (n = 16) 0 (N = 0) 6.2 (n = 1) 6.2 (n = 0)
Gall bladder Adenocarcinoma (n = 36) 2.7 (n = 1) 5.5 (n = 2) 8.2 (n = 3)
Endometrium Serous carcinoma (n = 31) 3.2 (n = 1) 12.9 (n = 4) 16.1 (n = 5)
Esophagus Squamous cell carcinoma (n = 32) 0 (n = 0) 3.1 (n = 1) 3.1 (n = 1)
Kidney Papillary cancer (n = 24) 4.1 (n = 1) 0 (n = 0) 4.1 (n = 1)
Larynx Squamous cell carcinoma (n = 31) 3.2 (n = 1) 3.2 (n = 1) 6.4 (n = 2)
Liver Hepatocellular carcinoma (n = 68) 1.5 (n = 1) 2.9 (n = 2) 4.4 (n = 3)
Lung (n = 125) Large cell cancer (n = 20) 5 (n = 1) 5 (n = 1) 10 (n = 2)
Squamous cell carcinoma (n = 39) 0 (n = 0) 2.6 (n = 1) 2.6 (n = 1)
Adenocarcinoma (n = 66) 0 (n = 0) 1.5 (n = 1) 1.5 (n = 1)
Ovary (n = 71) Endometroid cancer (n = 33) 3 (n = 1) 3 (n = 1) 6 (n = 2)
Serous cancer (n = 38) 2.6 (n = l) 5.2 (n = 2) 7.8 (n = 3)
Pancreas Adenocarcinoma (n = 44) 4.5 (n = 2) 0 (n = 0) 4.5 (n = 2)
Prostate Adenocarcinoma, castration-resistant (n = 34) 0 (n = 0) 2.9 (n = 1) 2.9 (n = 1)
Stomach Intestinal adenocarcinoma (n = 42) 4.7 (n = 2) 2.3 (n = 1) 7 (n = 3)
Uterus, cervix CIN III (n = 24) 4.1 (n = 1) 0 (n = 0) 4.1 (n = 1)
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Analysis of the VEGFA gene amplification by FISH
on TMA and high resolution CGH microarrays
in human tumour xenografts
To confirm the presence of the VEGFA gene amplification
by an independent method, we analysed 194 fresh-frozen
tissue specimens obtained from human tumour-derived
xenografts using CGH. The VEGFA gene locus status of
these 194 models was previously analyses using corre-
sponding FFPE samples by means of our FISH probe. FISH
analysis revealed 4 samples harbouring VEGFA amplifi-
cation namely specimens obtained from gastric, breast,
non-small-cell lung cancer (NSCLC) and sarcoma, with
prevalence rates between 5 and 16 % (Table 2 and Sup-
plementary Table 4 for complete listing). In addition, as for
the human multi tumour-TMA above described, we have
further categorized the amplified samples using a second
selection criterion discriminating between high (i.e. [10
VEGFA/Chr6), average (5–10 VEGFA/Chr6) or low num-
ber of gene copies (Supplementary Table 5 and Supple-
mentary Table 6). FISH results were confirmed for all 4
samples by CGH. Figure 3 displays representative high-
resolution CGH microarray profiles of one melanoma
without amplification and two VEGFA amplified tumours
(a gastric cancer and NSCLC). By means of CGH analysis,
we also investigated the structure of the VEGFA amplicon.
Whereas the gastric cancer sample (Fig. 3b) showed a
larger amplified region (approx. 20 Megabases), the
NSCLC sample (Fig. 3c) was characterized by a focal
amplicon covering a small region of 5.85 Mb.
In addition, we investigated the copy number status of
Chr6 and observed polisomy in 6 of the 24 analysed
tumour types such as bladder, colon and small cell lung
cancer, pleura mesothelioma, NSCLC and NSCLC of the
squamous cell subtype (Table 2 and Supplementary
Table 4). Moreover our analysis revealed that among all
tested tumour types only NSCLC, showed both amplified
and polysomic cases.
Discussion
In this study for the first time, we comprehensively sur-
veyed the VEGFA gene status in a broad range of human
cancers. Our analysis reviled that, albeit with low inci-
dence, VEGFA amplification was detected regularly in
several tumour entities, whereas it was always absent in
normal tissues. Furthermore we also validated the reli-
ability of FISH test as a diagnostic tool to assess the
VEGFA gene status.
Given its role in the growth and development of different
tumour types, VEGFA is considered to be one of the most
attractive targets in cancer therapy. We previously reported
that the presence of VEGFA gene locus (6p12) amplification
Fig. 1 Visualization of VEGFA
gene locus 6p12 amplification
by FISH. The green and red
signals correspond to
centromere 6 and VEGFA gene
region, respectively.
a Representative pictures of
gastric cancer with normal and
b amplified VEGFA gene status.
c Representative pictures of
lung cancer with normal and
d amplified VEGFA gene status.
(Color figure online)
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characterizes a small but considerable aggressive subgroup
of CRC [6]. On a total number of 1,501 primary unselected
CRC patients we observed VEGFA gene locus amplification
in 3–6 % of two independent cohorts, respectively. The
genomic aberration, in both cohorts, was significantly asso-
ciated with unfavourable prognostic features and poorer
survival time [6]. Afterwards, we wanted to address whether
VEGFA locus amplification is a phenomenon limited to CRC
or is a common alteration in several tumour types. The study
was as well motivated by the hypothesis that the VEGFA
gene amplification could be useful as predictive biomarker of
clinical response in patients considered for BV or tyrosine
kinase inhibitors treatment in addition to chemotherapy.
Here, we assessed the VEGFA gene copy number status in a
total of 2,837 tumours and 315 normal tissue specimens.
VEGFA amplification was observed in different types of
malignancies, such as those of the lung (large cell cancer),
stomach (adenocarcinoma intestinal type), ovary (endo-
metroid as well as serous carcinoma), gall bladder (adeno-
carcinoma), uterus cervix, endometrium (serous carcinoma),
Fig. 2 Micro-vessels density is increased in CRC VEGFA amplified samples. a Representative pictures of CD31 stained CRC specimens. Scale
bar correspond to 100 lm. b MVD quantification
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kidney (papillary renal cancer), larynx (squamous cell car-
cinoma) and liver (hepatocellular carcinoma).
The prevalence rates of VEGFA amplification in these
tumours varied between 1.5 and 5 %. Based on CGH
profiling studies, gain of Chr6p has been described in dif-
ferent tumour types, such as hepatocellular carcinoma,
osteosarcoma, retinoblastoma, Merkel cell carcinoma and
carcinosarcoma [21]. Additionally, focal gain and ampli-
fication of the VEGFA gene was also reported in 4 out of
103 hepatocellular carcinomas [22] and in 4 out of 371
lung cancers [23, 24]. This is in line with our findings from
the multi-tumour TMA, in which we also report the
genomic amplification of the VEGFA gene in these two
tumour types at comparable frequency. Thus, our results
are in line previously reported genomic profiling studies,
which indicated the presence of specific genomic aberra-
tions at rather low prevalence, but consistently observed
throughout different tumour types.
Interestingly, some tumour types that did not show the
VEGFA gene amplification were characterized by the
polysomy of Chr6. Among these we observed breast cancer
samples (mucinous and ductal cancer) and esophageal
carcinoma specimens (squamous cell carcinoma). How-
ever, the impact of polysomy in cancer and its usage as a
diagnostic marker is controversially discussed [25, 26].
Thus, additional studies specifically addressing this ques-
tion are needed. Moreover, for the future we seek to cor-
relate the VEGFA gene locus status (e.g. amplification or
polisomy) with VEGFA protein levels.
Furthermore, we observed that VEGFA amplification
was exclusively present in malignant epithelial tumours,
whereas haematological neoplasias as well as soft tissue
sarcomas were completely negative for such genomic
aberrations. Concerning haematological neoplasias, our
data are in line with recently reported results [27]. About
soft tissue sarcomas, taking advantage of new generation
Fig. 3 Representative CGH profiles of the VEGFA genomic region.
Depicted area focus on Chromosome 6—VEGFA locus. a Melanoma
sample with normal VEGFA gene copy number. b, c Gastric cancer
and NSCLC samples showing VEGFA gene amplification,
respectively. Red arrows point towards the VEGFA gene position at
6p12. The vertical dotted red line denotes the position of the
centromere of the Chromosome. Horizontal blue lines represent the
segments inferred by the CGH calling algorithm. (Color figure online)
Table 2 Rates of VEGFA gene locus amplification in selected human tumour xenografts as evaluated by FISH
Organ Tumor type Amplification (%) Polysomy (%) Amplification ? polysomy (%)
Bladder Bladder cancer (n = 6) 0 16 (n = 1) 16 (n = 1)
Breast Mammary cancer (n = l2) 8 (n = 1) 0 8 (n = 1)
Intestine Colon cancer (n = 29) 0 3 (n = 1) 3 (n = 1)
Lung (n = 43) Non small cell lung cancer (n = 20) 5 (n = 1) 15 (n = 3) 20 (n = 4)
Non small cell lung cancer, epidemoid (n = 11) 0 27 (n = 3) 27 (n = 3)
Small cell lung cancer (n = 5) 0 20 (n = 1) 20 (n = 1)
Pleuramesothelioma (n = 6) 0 16 (n = 1) 16 (n = 1)
Skin Sarcoma (n = 10) 10 (n = 1) 0 10 (n = 1)
Stomach Gastric cancer (n = 6) 16 (n = 1) 0 16 (n = 1)
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sequencing (NGS), previous work has globally investigated
the incidence of genomic aberrations in soft tissue sarco-
mas, observing VEGFA amplification in about 1.9 % of
tested specimens (n = 207) [28]. Furthermore, VEGFA
overexpression has been reported to be a frequent event in
Ewing’s sarcoma, being associated with increased angio-
genesis, MVD and modulating patient’s survival [29, 30].
The discrepancy observed concerning the VEGFA status
with our results could be explained by relative small
number size of our investigated cohort of such cases.
Interestingly, in osteosarcoma, VEGFA amplification has
been ranked among the most frequent genetic amplifica-
tions being observed in more than 50 % of analysed sam-
ples [31]. However, unfortunately our TMA lacks of any
osteosarcoma samples, thus we cannot make any direct
comparison to previously reported data for this tumour
entity. All together, these examples suggest that the role of
VEGFA amplification in specific sub-class of malignancies
deserves further and accurate investigations.
In addition, as VEGFA amplification in osteosarcoma has
been associated to an increase in MVD due to VEGFA
protein overproduction [31], we seek to evaluate MVD on a
small cohort of CRCs comprising amplified samples. In
accordance to previously reported data [31], we observed
that CRC samples harbouring VEGFA amplification present
with increased MVD compared to both not amplified and
polysomic specimens. MVD density status could modulate
the response to antiangiogenic therapy [32], thus our results
further underline the importance of using VEGFA status as a
potential tool to stratify patients. The use of anti-VEGFA
treatments and the partial success of these agents in CRC,
NSCLC and renal carcinoma (RCC), emphasizes the
importance for further stratification of patients in potential
responder and non-responders before therapy assignment.
The evaluation of gene amplification and deletion in tumour
specimens has been proven to serve as a meaningful tool to
predict response to therapy. For example, it has been clearly
demonstrated that breast cancer patients harbouring HER2
amplifications are highly sensitive to therapeutic agents
targeting HER2 protein (e.g. trastuzumab), while patients
without HER2 amplification receive little benefit from such a
treatment [7]. Thus, it is tempting to speculate that VEGFA
gene amplification might also be a useful biomarker for
sensitivity towards VEGFA-targeted therapies, as for HER2
amplification. Further studies specifically addressing this
point are needed.
Most of our results were obtained using a FISH-based
analysis. Importantly, in this work we also tested the
consistency of our FISH probe by directly comparing
FISH-obtained data to CGH results acquired analysing
tumour xenograft samples. The two methodologies dis-
played high concordant results thus fostering the reliability
of FISH data. To conclude, our results demonstrate that
VEGFA gene locus amplification is not limited to CRC but
is broadly observed across different tumour species.
Moreover, we demonstrated that our FISH test is robust
and reliable for clinical diagnostic tool, independently of
tissue type, and clearly facilitates the identification of the
VEGFA gene locus amplification as well as the polysomy
of Chr6.
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